FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports Second Quarter Revenue at High End of Guidance and Earnings Per Share Above Guidance
Company generates strong operating margin and cash position; narrows revenue and raises EPS guidance
PROVO, Utah — August 7, 2025 — Nu Skin
Enterprises Inc. (NYSE: NUS) today announced second quarter revenue at the high end of its guidance range and earnings per share exceeding guidance.
Executive Summary
Q2 2025 vs. Prior-year Quarter
|
Revenue
|
$386.1 million; (12.1)%
• 0.3% FX impact
or $1.4 million
|
||
|
Earnings Per Share (EPS)
|
$0.43 compared to $(2.38) or $0.21 excluding impairment and other charges
|
||
|
Customers
|
771,407; (14)%
|
||
|
Paid Affiliates
|
130,799; (16)%
|
||
|
Sales Leaders
|
29,593; (23)%
|
“We are pleased with our solid performance in the second quarter including our efforts to drive revenue at the high end of our guidance and significantly exceeding our
forecast for earnings per share,” said Ryan Napierski, Nu Skin president and CEO. “We are also pleased with our ongoing operational optimization efforts resulting in 8% operating margin despite top-line pressures on the business. Our Rhyz
Manufacturing segment continues to perform well with 17% year-over-year revenue growth.
“We also made significant progress during the quarter in building sales leader engagement and alignment for our key initiatives for late 2025 and 2026. We are on
schedule for a mid-Q4 limited preview of our Prysm iO intelligent wellness device, the next innovation in our line of the world’s best-selling beauty and wellness device systems.1 We believe this AI-powered wellness assessment device
will stimulate growth in our nutritional supplements business by providing personalized product recommendations and subscriptions to drive customer lifetime value. Additionally, leveraging success principles for developing markets gleaned from
Latin America, where we had 107% year-over-year revenue growth, we are on track with our plans for Q4 market pre-opening activities in India with a formal launch anticipated for mid-2026. We remain confident in our strategy going forward to return
to growth and drive shareholder value.”
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 2
|
Q2 2025 Year-over-year Operating Results
|
Revenue
|
$386.1 million compared to $439.1 million
• 0.3% FX impact
or $1.4 million
|
||
|
Gross Margin
|
68.8% compared to 70.0%
• Nu Skin business
was 77.5% compared to 76.1%
|
||
|
Selling Expenses
|
33.2% compared to 37.7%
• Nu Skin business
was 40.0% compared to 42.2%
|
||
|
G&A Expenses
|
27.6% compared to 26.9%
|
||
|
Operating Margin
|
8.0% compared to (28.6)% or 5.4% excluding impairment and other charges
|
||
|
Interest Expense
|
$2.5 million compared to $6.7 million
|
||
|
Other Income/ (Expense)
|
$(0.8) million compared to $0.6 million
|
||
|
Income Tax Rate
|
23.0% compared to 10.2% or 41.4% excluding impairment and other charges
|
||
|
EPS
|
$0.43 compared to $(2.38) or $0.21 excluding impairment and other charges
|
Stockholder Value
|
Dividend Payments
|
$3.0 million
|
||
|
Stock Repurchases
|
$0.0 million
• $157.4 million
remaining in authorization
|
Q3 and Full-year 2025 Outlook
|
Q3 2025 Revenue
|
$360 to $390 million; (16)% to (9)% or (13)% to (5)% excluding Mavely 2024 revenue
• Approximately
(1)% FX impact
|
||
|
Q3 2025 EPS
|
$0.25 to $0.35
|
||
|
2025 Revenue
|
$1.48 to $1.55 billion; (15)% to (11)% or (11)% to (7)% excluding Mavely 2024 revenue
• Approximately
(1)% FX impact
|
||
|
2025 EPS
|
$3.05 to $3.25 or $1.15 to $1.35 excluding Mavely gain and other charges
|
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 3
|
“We are encouraged by the positive results of our ongoing efforts to improve overall profitability, which has generated significant cash and
further strengthened our balance sheet,” said James D. Thomas, chief financial officer. “Notably, we’ve achieved our goal of reaching a positive net cash position ahead of schedule, marking the first time in more than 4 years that we’ve been in
such a position. Based on our first-half results and greater clarity into performance and consumer sentiment through the end of the year, we are narrowing our revenue and increasing our earnings guidance. For 2025, we project revenue of $1.48
billion to $1.55 billion and earnings per share of $3.05 to $3.25 with adjusted EPS of $1.15 to $1.35. For the third quarter, we project revenue between $360 million and $390 million, with earnings per share in the range of $0.25 to $0.35.”
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access
the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 22, 2025.
About Nu Skin Enterprises Inc.
The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness
company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin®
personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty and wellness device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies
focused on innovation within the beauty, wellness and lifestyle categories.
1Source Euromonitor International Limited; At-Home Beauty and Wellness Device Systems on a total retail level in RSP, excluding salon
services that may offer packages, research conducted April – May 2024.
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 4
|
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s
expectations regarding the macro environment and the company’s performance, growth and growth opportunities, shareholder value, product previews and launches and their potential benefits to the business, investments, initiatives, and new market
expansion and its timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and
other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “schedule,”
“accelerate,” “project,” “remain,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.
The forward-looking statements and related assumptions involve important risks and uncertainties that could cause actual results and outcomes to
differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
| • |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and
selling activities on a sustained basis;
|
| • |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted
or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased
scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
|
| • |
economic conditions and events globally;
|
| • |
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the
company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
|
| • |
competitive pressures in the company’s markets;
|
| • |
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
|
| • |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
| • |
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
|
| • |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland
China on our business operations and results;
|
| • |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
| • |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
| • |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and
increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
|
| • |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue
selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
|
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of
associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company
assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 5
|
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
Earnings per share, operating margin and income tax rate, each excluding the gain from the Mavely sale, restructuring charges, impairment charges,
unrealized investment loss, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.
| • |
Restructuring charges, impairment charges, and unrealized investment losses are not part of the ongoing operations of our underlying business;
|
| • |
Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025; and
|
| • |
the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not
typical for our ongoing operations.
|
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these
items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, general & administrative expenses, operating margin, income tax rate and revenue growth rate
calculated under GAAP, below.
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 6
|
The following table sets forth revenue for the three-month periods ended June 30, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
|
Three Months Ended
June 30, |
Constant-
Currency
|
|||||||||||||||
|
2025
|
2024
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Americas
|
$
|
72,946
|
$
|
84,935
|
(14.1
|
)%
|
(8.2
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
50,834
|
60,341
|
(15.8
|
)%
|
(17.3
|
)%
|
||||||||||
|
Mainland China
|
53,224
|
64,710
|
(17.7
|
)%
|
(18.0
|
)%
|
||||||||||
|
Japan
|
44,550
|
42,587
|
4.6
|
%
|
(3.1
|
)%
|
||||||||||
|
Europe & Africa
|
37,328
|
40,714
|
(8.3
|
)%
|
(13.0
|
)%
|
||||||||||
|
South Korea
|
34,068
|
44,119
|
(22.8
|
)%
|
(21.3
|
)%
|
||||||||||
|
Hong Kong/Taiwan
|
27,527
|
33,846
|
(18.7
|
)%
|
(21.1
|
)%
|
||||||||||
|
Nu Skin Other
|
427
|
(4
|
)
|
10,775.0
|
%
|
10,775.0
|
%
|
|||||||||
|
Total Nu Skin
|
320,904
|
371,248
|
(13.6
|
)%
|
(13.9
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
60,400
|
51,473
|
17.3
|
%
|
17.3
|
%
|
||||||||||
|
Rhyz Other
|
4,834
|
16,360
|
(70.5
|
)%
|
(70.5
|
)%
|
||||||||||
|
Total Rhyz
|
65,234
|
67,833
|
(3.8
|
)%
|
(3.8
|
)%
|
||||||||||
|
Total
|
$
|
386,138
|
$
|
439,081
|
(12.1
|
)%
|
(12.4
|
)%
|
||||||||
The following table sets forth revenue for the six-month periods ended June 30, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
|
Six Months Ended
June 30,
|
Constant-
Currency
|
|||||||||||||||
|
2025
|
2024
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Americas
|
$
|
142,004
|
$
|
159,966
|
(11.2
|
)%
|
(5.0
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
103,006
|
120,406
|
(14.5
|
)%
|
(14.7
|
)%
|
||||||||||
|
Mainland China
|
100,999
|
125,777
|
(19.7
|
)%
|
(19.2
|
)%
|
||||||||||
|
Japan
|
87,315
|
86,823
|
0.6
|
%
|
(1.9
|
)%
|
||||||||||
|
Europe & Africa
|
70,349
|
82,987
|
(15.2
|
)%
|
(16.3
|
)%
|
||||||||||
|
South Korea
|
66,583
|
85,082
|
(21.7
|
)%
|
(17.4
|
)%
|
||||||||||
|
Hong Kong/Taiwan
|
55,974
|
64,312
|
(13.0
|
)%
|
(13.0
|
)%
|
||||||||||
|
Nu Skin Other
|
956
|
668
|
43.1
|
%
|
43.1
|
%
|
||||||||||
|
Total Nu Skin
|
627,186
|
726,021
|
(13.6
|
)%
|
(12.1
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
115,690
|
101,775
|
13.7
|
%
|
13.7
|
%
|
||||||||||
|
Rhyz Other
|
7,752
|
28,591
|
(72.9
|
)%
|
(72.9
|
)%
|
||||||||||
|
Total Rhyz
|
123,442
|
130,366
|
(5.3
|
)%
|
(5.3
|
)%
|
||||||||||
|
Total
|
$
|
750,628
|
$
|
856,387
|
(12.3
|
)%
|
(11.1
|
)%
|
||||||||
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 7
|
The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods
ended June 30, 2025 and 2024.
|
Three Months Ended
June 30,
|
||||||||||||
|
2025
|
2024
|
Change
|
||||||||||
|
Customers
|
||||||||||||
|
Americas
|
240,477
|
226,626
|
6
|
%
|
||||||||
|
Southeast Asia/Pacific
|
72,814
|
88,662
|
(18
|
)%
|
||||||||
|
Mainland China
|
117,325
|
179,021
|
(34
|
)%
|
||||||||
|
Japan
|
105,961
|
109,357
|
(3
|
)%
|
||||||||
|
Europe & Africa
|
126,146
|
143,336
|
(12
|
)%
|
||||||||
|
South Korea
|
67,313
|
99,358
|
(32
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
41,371
|
47,154
|
(12
|
)%
|
||||||||
|
Total Customers
|
771,407
|
893,514
|
(14
|
)%
|
||||||||
|
Paid Affiliates
|
||||||||||||
|
Americas
|
28,827
|
29,531
|
(2
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
21,092
|
29,701
|
(29
|
)%
|
||||||||
|
Mainland China
|
19,399
|
24,404
|
(21
|
)%
|
||||||||
|
Japan
|
19,605
|
21,575
|
(9
|
)%
|
||||||||
|
Europe & Africa
|
15,320
|
17,402
|
(12
|
)%
|
||||||||
|
South Korea
|
16,986
|
22,116
|
(23
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
9,570
|
10,757
|
(11
|
)%
|
||||||||
|
Total Paid Affiliates
|
130,799
|
155,486
|
(16
|
)%
|
||||||||
|
Sales Leaders
|
||||||||||||
|
Americas
|
5,971
|
6,070
|
(2
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
4,126
|
5,601
|
(26
|
)%
|
||||||||
|
Mainland China
|
5,790
|
10,266
|
(44
|
)%
|
||||||||
|
Japan
|
5,882
|
6,116
|
(4
|
)%
|
||||||||
|
Europe & Africa
|
2,695
|
3,432
|
(21
|
)%
|
||||||||
|
South Korea
|
3,066
|
4,689
|
(35
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
2,063
|
2,418
|
(15
|
)%
|
||||||||
|
Total Sales Leaders
|
29,593
|
38,592
|
(23
|
)%
|
||||||||
| ● |
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales
force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
|
| ● |
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our
markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
|
| ● |
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain
qualification requirements as of the end of each month of the quarter.
|
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 8
|
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Revenue
|
$
|
386,138
|
$
|
439,081
|
$
|
750,628
|
$
|
856,387
|
||||||||
|
Cost of sales
|
120,405
|
131,904
|
237,934
|
255,146
|
||||||||||||
|
Gross profit
|
265,733
|
307,177
|
512,694
|
601,241
|
||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling expenses
|
128,228
|
165,463
|
246,774
|
319,005
|
||||||||||||
|
General and administrative expenses
|
106,725
|
117,921
|
219,929
|
242,487
|
||||||||||||
|
Restructuring and impairment expenses
|
—
|
149,350
|
25,114
|
156,484
|
||||||||||||
|
Total operating expenses
|
234,953
|
432,734
|
491,817
|
717,976
|
||||||||||||
|
|
||||||||||||||||
|
Operating income (loss)
|
30,780
|
(125,557
|
)
|
20,877
|
(116,735
|
)
|
||||||||||
|
Interest expense
|
2,526
|
6,720
|
5,809
|
14,045
|
||||||||||||
|
Gain on sale of business
|
—
|
—
|
176,162
|
—
|
||||||||||||
|
Other income (expense), net
|
(843
|
)
|
629
|
(29,218
|
)
|
233
|
||||||||||
|
Income (loss) before provision for income taxes
|
27,411
|
(131,648
|
)
|
162,012
|
(130,547
|
)
|
||||||||||
|
Provision (benefit) for income taxes
|
6,292
|
(13,390
|
)
|
33,378
|
(11,756
|
)
|
||||||||||
|
Net income (loss)
|
$
|
21,119
|
$
|
(118,258
|
)
|
$
|
128,634
|
$
|
(118,791
|
)
|
||||||
|
Net income (loss) per share:
|
||||||||||||||||
|
Basic
|
$
|
0.43
|
$
|
(2.38
|
)
|
$
|
2.59
|
$
|
(2.39
|
)
|
||||||
|
Diluted
|
$
|
0.43
|
$
|
(2.38
|
)
|
$
|
2.59
|
$
|
(2.39
|
)
|
||||||
|
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
|
Basic
|
49,441
|
49,688
|
49,601
|
49,613
|
||||||||||||
|
Diluted
|
49,499
|
49,688
|
49,748
|
49,613
|
||||||||||||
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 9
|
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
|
June 30,
2025
|
December 31,
2024
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
264,159
|
$
|
186,883
|
||||
|
Current investments
|
1,211
|
11,111
|
||||||
|
Accounts receivable, net
|
59,703
|
50,784
|
||||||
|
Inventories, net
|
180,377
|
190,242
|
||||||
|
Prepaid expenses and other
|
66,103
|
72,643
|
||||||
|
Current assets held for sale
|
—
|
26,936
|
||||||
|
Total current assets
|
571,553
|
538,599
|
||||||
|
Property and equipment, net
|
374,207
|
379,595
|
||||||
|
Operating lease right-of-use assets
|
77,736
|
72,605
|
||||||
|
Goodwill
|
83,625
|
83,625
|
||||||
|
Other intangible assets, net
|
45,937
|
74,278
|
||||||
|
Other assets
|
290,635
|
298,008
|
||||||
|
Long-term assets held for sale
|
—
|
22,204
|
||||||
|
Total assets
|
$
|
1,443,693
|
$
|
1,468,914
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
28,734
|
$
|
34,880
|
||||
|
Accrued expenses
|
220,172
|
217,808
|
||||||
|
Current portion of long-term debt
|
35,000
|
30,000
|
||||||
|
Current liabilities held for sale
|
—
|
13,919
|
||||||
|
Total current liabilities
|
283,906
|
296,607
|
||||||
|
Operating lease liabilities
|
61,837
|
58,439
|
||||||
|
Long-term debt
|
213,900
|
363,613
|
||||||
|
Other liabilities
|
96,296
|
97,475
|
||||||
|
Long-term liabilities held for sale
|
—
|
1,325
|
||||||
|
Total liabilities
|
655,939
|
817,459
|
||||||
|
Stockholders’ equity:
|
||||||||
|
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
|
Additional paid-in capital
|
627,515
|
627,787
|
||||||
|
Treasury stock, at cost – 41.1 million and 40.8 million shares
|
(1,560,411
|
)
|
(1,563,614
|
)
|
||||
|
Accumulated other comprehensive loss
|
(114,058
|
)
|
(124,758
|
)
|
||||
|
Retained earnings
|
1,834,617
|
1,711,949
|
||||||
|
Total stockholders' equity
|
787,754
|
651,455
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
1,443,693
|
$
|
1,468,914
|
||||
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 10
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Operating Income
|
$
|
30,780
|
$
|
(125,557
|
)
|
$
|
20,877
|
$
|
(116,735
|
)
|
||||||
|
Impact of other charges(1)
|
-
|
-
|
7,966
|
-
|
||||||||||||
|
Impact of restructuring and impairment
|
-
|
149,350
|
25,114
|
156,484
|
||||||||||||
|
Adjusted operating income
|
$
|
30,780
|
$
|
23,793
|
$
|
53,957
|
$
|
39,749
|
||||||||
|
Operating margin
|
8.0
|
%
|
(28.6
|
)%
|
2.8
|
%
|
(13.6
|
)%
|
||||||||
|
Operating margin, excluding certain charges
|
8.0
|
%
|
5.4
|
%
|
7.2
|
%
|
4.6
|
%
|
||||||||
|
Revenue
|
$
|
386,138
|
$
|
439,081
|
$
|
750,628
|
$
|
856,387
|
||||||||
(1) Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of
transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 11
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate
(in thousands, except for per share amounts)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Provision (benefit) for income taxes
|
$
|
6,292
|
$
|
(13,390
|
)
|
$
|
33,378
|
$
|
(11,756
|
)
|
||||||
|
Impact of other charges(1) on provision for income taxes
|
-
|
-
|
725
|
-
|
||||||||||||
|
Impact of restructuring and impairment on provision for income taxes
|
-
|
20,715
|
5,433
|
23,071
|
||||||||||||
|
Impact of gain on Mavely sale on provision for income taxes
|
-
|
-
|
(31,104
|
)
|
-
|
|||||||||||
|
Impact of unrealized investment loss on provision for income taxes
|
-
|
-
|
6,074
|
-
|
||||||||||||
|
Provision for income taxes, excluding impact of Mavely gain and certain charges
|
$
|
6,292
|
$
|
7,325
|
$
|
14,506
|
$
|
11,315
|
||||||||
|
Income before provision for income taxes
|
27,411
|
(131,648
|
)
|
162,012
|
(130,547
|
)
|
||||||||||
|
Impact of other charges(1)
|
-
|
-
|
7,966
|
|||||||||||||
|
Impact of restructuring and impairment expense:
|
-
|
149,350
|
25,114
|
156,484
|
||||||||||||
|
Impact of gain on Mavely sale
|
-
|
-
|
(176,162
|
)
|
-
|
|||||||||||
|
Impact of unrealized investment loss
|
-
|
-
|
28,077
|
-
|
||||||||||||
|
Income before provision for income taxes, excluding impact certain charges
|
$
|
27,411
|
$
|
17,702
|
$
|
47,007
|
$
|
25,937
|
||||||||
|
Effective tax rate
|
23.0
|
%
|
10.2
|
%
|
20.6
|
%
|
9.0
|
%
|
||||||||
|
Effective tax rate, excluding impact of Mavely gain and certain charges
|
23.0
|
%
|
41.4
|
%
|
30.9
|
%
|
43.6
|
%
|
||||||||
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 12
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Net income
|
$
|
21,119
|
$
|
(118,258
|
)
|
$
|
128,634
|
$
|
(118,791
|
)
|
||||||
|
Impact of other charges
|
||||||||||||||||
|
Other charges(1)
|
-
|
-
|
7,966
|
-
|
||||||||||||
|
Tax impact
|
-
|
-
|
(725
|
)
|
-
|
|||||||||||
|
Impact of restructuring and impairment expense:
|
||||||||||||||||
|
Restructuring and impairment
|
-
|
149,350
|
25,114
|
156,484
|
||||||||||||
|
Tax impact
|
-
|
(20,715
|
)
|
(5,433
|
)
|
(23,071
|
)
|
|||||||||
|
Impact of gain on Mavely sale
|
||||||||||||||||
|
Gain on Mavely sale
|
-
|
-
|
(176,162
|
)
|
-
|
|||||||||||
|
Tax impact
|
-
|
-
|
31,104
|
-
|
||||||||||||
|
Impact of unrealized investment loss
|
||||||||||||||||
|
Unrealized investment loss
|
-
|
-
|
28,077
|
-
|
||||||||||||
|
Tax impact
|
-
|
-
|
(6,074
|
)
|
-
|
|||||||||||
|
Adjusted net income
|
$
|
21,119
|
$
|
10,377
|
$
|
32,501
|
$
|
14,622
|
||||||||
|
Diluted earnings per share
|
$
|
0.43
|
$
|
(2.38
|
)
|
$
|
2.59
|
$
|
(2.39
|
)
|
||||||
|
Diluted earnings per share, excluding impact of Mavely gain and certain charges
|
$
|
0.43
|
$
|
0.21
|
$
|
0.65
|
$
|
0.29
|
||||||||
|
Weighted-average common shares outstanding (000)
|
49,499
|
49,688
|
49,748
|
49,613
|
||||||||||||
|
Nu Skin Enterprises Reports Second Quarter 2025 Financial Results
|
page 13
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings
Per Share
|
Year ended December 31, 2025
|
||||||||
|
Low end
|
High end
|
|||||||
|
Earnings Per Share
|
$
|
3.05
|
$
|
3.25
|
||||
|
Impact of other charges
|
||||||||
|
Other charges(1)
|
0.16
|
0.16
|
||||||
|
Tax impact
|
(0.01
|
)
|
(0.01
|
)
|
||||
|
Impact of restructuring and impairment expense:
|
||||||||
|
Restructuring and impairment
|
0.50
|
0.50
|
||||||
|
Tax impact
|
(0.11
|
)
|
(0.11
|
)
|
||||
|
Impact of gain on Mavely sale
|
||||||||
|
Gain on Mavely sale
|
(3.50
|
)
|
(3.50
|
)
|
||||
|
Tax impact
|
0.62
|
0.62
|
||||||
|
Impact of unrealized investment loss
|
||||||||
|
Unrealized investment loss
|
0.56
|
0.56
|
||||||
|
Tax impact
|
(0.12
|
)
|
(0.12
|
)
|
||||
|
Adjusted EPS
|
$
|
1.15
|
$
|
1.35
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates
(in thousands)
|
Three months ended
September 30, 2025
|
Year ended
December 31, 2025
|
|||||||||||||||
|
Low end
|
High end
|
Low end
|
High end
|
|||||||||||||
|
2024 Revenue
|
$
|
430,145
|
$
|
430,145
|
$
|
1,732,084
|
$
|
1,732,084
|
||||||||
|
Less: Mavely 2024 Revenue
|
18,391
|
18,391
|
69,620
|
69,620
|
||||||||||||
|
Adjusted 2024 Revenue
|
$
|
411,754
|
$
|
411,754
|
$
|
1,662,464
|
$
|
1,662,464
|
||||||||
|
Revenue Growth Rate
|
(16
|
)%
|
(9
|
)%
|
(15
|
)%
|
(11
|
)%
|
||||||||
|
Revenue Growth Rate, excluding Mavely
|
(13
|
)%
|
(5
|
)%
|
(11
|
)%
|
(7
|
)%
|
||||||||
|
2025 Forecasted Revenue
|
$
|
360,000
|
$
|
390,000
|
$
|
1,480,000
|
$
|
1,550,000
|
||||||||
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577